- Home
- BCV vs GUTS Comparison
BCV vs GUTS Comparison
Compare BCV & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- GUTS
- Stock Information
- Founded
- BCV 1971
- GUTS 2010
- Country
- BCV United States
- GUTS United States
- Employees
- BCV N/A
- GUTS N/A
- Industry
- BCV Finance/Investors Services
- GUTS
- Sector
- BCV Finance
- GUTS
- Exchange
- BCV Nasdaq
- GUTS NYSE
- Market Cap
- BCV 106.0M
- GUTS 110.1M
- IPO Year
- BCV N/A
- GUTS 2024
- Fundamental
- Price
- BCV $17.73
- GUTS $1.90
- Analyst Decision
- BCV
- GUTS Buy
- Analyst Count
- BCV 0
- GUTS 2
- Target Price
- BCV N/A
- GUTS $18.00
- AVG Volume (30 Days)
- BCV 26.3K
- GUTS 269.4K
- Earning Date
- BCV 01-01-0001
- GUTS 02-02-2025
- Dividend Yield
- BCV 8.13%
- GUTS N/A
- EPS Growth
- BCV N/A
- GUTS N/A
- EPS
- BCV N/A
- GUTS N/A
- Revenue
- BCV N/A
- GUTS $97,000.00
- Revenue This Year
- BCV N/A
- GUTS N/A
- Revenue Next Year
- BCV N/A
- GUTS N/A
- P/E Ratio
- BCV N/A
- GUTS N/A
- Revenue Growth
- BCV N/A
- GUTS N/A
- 52 Week Low
- BCV $14.09
- GUTS $1.74
- 52 Week High
- BCV $18.11
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- BCV 39.38
- GUTS 38.98
- Support Level
- BCV $18.29
- GUTS $2.00
- Resistance Level
- BCV $18.38
- GUTS $2.58
- Average True Range (ATR)
- BCV 0.18
- GUTS 0.21
- MACD
- BCV -0.11
- GUTS -0.03
- Stochastic Oscillator
- BCV 0.00
- GUTS 7.13
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.